In a significant development in the pharmaceutical industry, Pfizer has successfully acquired the obesity drug startup Metsera for $10 billion, triumphing over Novo Nordisk after a heated bidding war. This acquisition positions Pfizer strongly in the competitive weight-loss market. Despite Novo Nordisk’s attempts to counter with increased bids, including a reported proposal of up to $10 billion, the Danish company has ultimately conceded defeat. The intense rivalry included strategic maneuvers, with analysts highlighting the aggressive nature of the bidding process and the implications for both companies in the ongoing pursuit of dominating the obesity treatment sector. With this acquisition, Pfizer solidifies its foothold in the obesity drug market while Novo Nordisk must now pivot to identify new targets.